<abstract xmlns="http://www.w3.org/1999/xhtml">Background. Mild hyperthermia (mHT) increases the tumor perfusion and vascular permeability, and reduces the interstitial fluid pressure, resulting in better intra-tumoral bioavailability of low molecular weight drugs. This approach is potentially also attractive for delivery of therapeutic macromolecules, such as antibodies. Here, we investigated the effects of mHT on the stability, immunological and pharmacological properties of Herceptin®, a clinically approved antibody, targeting the human epidermal growth factor receptor 2 (HER-2) overexpressed in breast cancer. Results. Herceptin® was heated to 37°C (control) and 42°C (mHT) for 1 hour. Formation of Herceptin® aggregates was measured using Nile Red assay. mHT did not result in additional Herceptin® aggregates compared to 37°C, showing the Herceptin® stability is unchanged. Immunological and pharmacological properties of Herceptin® were evaluated following mHT using HER-2 positive breast cancer cells (BT-474). Exposure of Herceptin® to mHT preserved recognition and binding affinity of Herceptin® to HER-2. Western-blot and cell proliferation assays on BT-474 cells showed that mHT left the inhibitory activities of Herceptin® unchanged. Conclusions. The stability, and the immunological and pharmacological properties of Herceptin® are not negatively affected by mHT. Further in-vivo studies are required to evaluate the influence of mHT on intra-tumoral bioavailability and therapeutic effectiveness of Herceptin®.</abstract>

Background. Mild hyperthermia (mHT) increases the tumor perfusion and vascular permeability, and reduces the interstitial fluid pressure, resulting in better intra-tumoral bioavailability of low molecular weight drugs. This approach is potentially also attractive for delivery of therapeutic macromolecules, such as antibodies. Here, we investigated the effects of mHT on the stability, immunological and pharmacological properties of Herceptin®, a clinically approved antibody, targeting the human epidermal growth factor receptor 2 (HER-2) overexpressed in breast cancer. Results. Herceptin® was heated to 37°C (control) and 42°C (mHT) for 1 hour. Formation of Herceptin® aggregates was measured using Nile Red assay. mHT did not result in additional Herceptin® aggregates compared to 37°C, showing the Herceptin® stability is unchanged. Immunological and pharmacological properties of Herceptin® were evaluated following mHT using HER-2 positive breast cancer cells (BT-474). Exposure of Herceptin® to mHT preserved recognition and binding affinity of Herceptin® to HER-2. Western-blot and cell proliferation assays on BT-474 cells showed that mHT left the inhibitory activities of Herceptin® unchanged. Conclusions. The stability, and the immunological and pharmacological properties of Herceptin® are not negatively affected by mHT. Further in-vivo studies are required to evaluate the influence of mHT on intra-tumoral bioavailability and therapeutic effectiveness of Herceptin®.

Mild hyperthermia influence on Herceptin® properties

Imaging Division, UMC Utrecht, Utrecht, the Netherlands

Radiology and Oncology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mild hyperthermia influence on Herceptin properties

{"article-title":{"content":["Mild hyperthermia influence on Herceptin","properties"],"sup":"®"}}

Background. Mild hyperthermia (mHT) increases the tumor perfusion and vascular permeability, and reduces the interstitial fluid pressure, resulting in better...

Mild hyperthermia influence on Herceptin^® properties

Pubblicato online: 03 mar 2015

Pagine: 41 - 49

Ricevuto: 17 ago 2014

Accettato: 24 ott 2014

DOI: https://doi.org/10.2478/raon-2014-0045

Parole chiave
mild hyperthermia, anticancer antibody, Herceptin®, breast cancer

© by Jean-Michel Escoffre

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mild hyperthermia influence on Herceptin® properties

Pubblicato online: 03 mar 2015

Pagine: 41 - 49

Ricevuto: 17 ago 2014

Accettato: 24 ott 2014

DOI: https://doi.org/10.2478/raon-2014-0045

Parole chiavemild hyperthermia, anticancer antibody, Herceptin®, breast cancer

© by Jean-Michel Escoffre

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mild hyperthermia influence on Herceptin^® properties

Parole chiave
mild hyperthermia, anticancer antibody, Herceptin®, breast cancer